

## **Acknowledgements**

*The study is sponsored by Roche Pharma AG, Grenzach-Wyhlen, Germany. Writing and editorial assistance for this abstract was provided by Physicians World Europe GmbH, Mannheim, Germany, and sponsored by Roche Pharma AG.*

## **Disclosures**

*All authors received support for their contribution to this study as well as medical writing support for the development of this congress abstract from Roche Pharma AG, Grenzach-Wyhlen, Germany.*

**H Schreiber:** Almirall, Biogen, Genzyme, Merck, Novartis, Roche, Teva<sup>2,3,5</sup>; Biogen, Novartis, Teva<sup>7</sup>; Biogen, Novartis, Roche<sup>9</sup>; **IK Penner:** Adamas Pharma, Almirall, Bayer Pharma, Biogen, Celgene, Genzyme, Merck, Novartis, Roche, Teva<sup>2,3</sup>; the German MS Society, Celgene, Novartis, Roche, Teva<sup>7</sup>; **C Cooper:** Roche<sup>10</sup>; **S Hieke-Schulz:** Roche<sup>10</sup>; **T Ziemssen:** Bayer<sup>2,11</sup>, Biogen<sup>2, 3, 9, 7</sup>, Genzyme/Sanofi<sup>2, 3, 9, 7</sup>, Novartis<sup>2, 3, 9, 7</sup>, Roche<sup>2, 3, 9, 7, 11</sup>, Teva<sup>2</sup>; Celgene<sup>2, 3</sup>, Almirall<sup>2</sup>, Merck<sup>2,3, 9</sup>

<sup>1</sup>Royalties; <sup>2</sup>speakers bureau or advisory board; <sup>3</sup>consulting fees; <sup>4</sup>board of trustees; <sup>5</sup>travel reimbursement; <sup>6</sup>writing assistance; <sup>7</sup>research grants; <sup>8</sup>data and safety monitoring boards; <sup>9</sup>data monitoring or steering committees; <sup>10</sup>employee; <sup>11</sup>shareholder, or financial interests